{"disease":{"id":"non-clear-cell-renal-cell-carcinoma","name":"non clear cell renal cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02915783","title":"A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT07488533","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05121948","title":"A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"HiberCell, Inc.","has_results":false},{"nct_id":"NCT01538238","title":"pazopanib_NCRCC,Ph2 STUDY","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Samsung Medical Center","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}